Search research articles
Contact Us
Filters
Showing results (1-10 of 118) with videos related to
Page
of 12
Sort By:
Statistics in Biopharmaceutical Research
|
June 4, 2020
Bayesian Methods in Regulatory Science
Gary L Rosner
Clinical Advances in Hematology & Oncology : H&O
|
May 10, 2018
Bayesian approaches to evaluating doses of drugs
Gary L Rosner
Biometrics
|
March 2, 2005
Bayesian monitoring of clinical trials with failure-time endpoints
Gary L Rosner
Biometrics
|
April 7, 2020
Discussion on "Predictively consistent prior effective sample sizes," by Beat Neuenschwander, Sebastian Weber, Heinz Schmidli, and Anthony O'Hagan
Gary L Rosner, Peter Müller
Statistics in Medicine
|
March 19, 2019
A Bayesian nonparametric causal inference model for synthesizing randomized clinical trial and real-world evidence
Chenguang Wang, Gary L Rosner
Statistics in Medicine
|
July 13, 2006
A semi-parametric Bayesian approach to average bioequivalence
Pulak Ghosh, Gary L Rosner
Biometrical Journal. Biometrische Zeitschrift
|
February 7, 2025
A Bias-Corrected Bayesian Nonparametric Model for Combining Studies With Varying Quality in Meta-Analysis
Pablo Emilio Verde, Gary L Rosner
Cancer Epidemiology
|
September 8, 2009
A projection of benefits due to fecal occult blood test for colorectal cancer
Dongfeng Wu, Diane Erwin, Gary L Rosner
Biometrics
|
January 13, 2006
MLE and Bayesian inference of age-dependent sensitivity and transition probability in periodic screening
Dongfeng Wu, Gary L Rosner, Lyle Broemeling
Biostatistics (Oxford, England)
|
October 13, 2006
Screening designs for drug development
David Rossell, Peter Müller, Gary L Rosner
Page
of 12
Search research articles
Search
Showing results (1-10 of 118) with videos related to
Sort By:
Page
of 12
Statistics in Biopharmaceutical Research
|
June 4, 2020
Bayesian Methods in Regulatory Science
Gary L Rosner
Clinical Advances in Hematology & Oncology : H&O
|
May 10, 2018
Bayesian approaches to evaluating doses of drugs
Gary L Rosner
Biometrics
|
March 2, 2005
Bayesian monitoring of clinical trials with failure-time endpoints
Gary L Rosner
Biometrics
|
April 7, 2020
Discussion on "Predictively consistent prior effective sample sizes," by Beat Neuenschwander, Sebastian Weber, Heinz Schmidli, and Anthony O'Hagan
Gary L Rosner, Peter Müller
Statistics in Medicine
|
March 19, 2019
A Bayesian nonparametric causal inference model for synthesizing randomized clinical trial and real-world evidence
Chenguang Wang, Gary L Rosner
Statistics in Medicine
|
July 13, 2006
A semi-parametric Bayesian approach to average bioequivalence
Pulak Ghosh, Gary L Rosner
Biometrical Journal. Biometrische Zeitschrift
|
February 7, 2025
A Bias-Corrected Bayesian Nonparametric Model for Combining Studies With Varying Quality in Meta-Analysis
Pablo Emilio Verde, Gary L Rosner
Cancer Epidemiology
|
September 8, 2009
A projection of benefits due to fecal occult blood test for colorectal cancer
Dongfeng Wu, Diane Erwin, Gary L Rosner
Biometrics
|
January 13, 2006
MLE and Bayesian inference of age-dependent sensitivity and transition probability in periodic screening
Dongfeng Wu, Gary L Rosner, Lyle Broemeling
Biostatistics (Oxford, England)
|
October 13, 2006
Screening designs for drug development
David Rossell, Peter Müller, Gary L Rosner
Page
of 12